

Improved personalized pain management by tailoring the need of analgesia and hypnotics









Company highlights





Oslo, Norway





Raised approx 8 mill Euro from investors and softfunding



Received grant on 2 million Euro with partners to develop new PainSensor



Developed **PainMonitoring Technology**

- · Real-time painmonitoring
- Pure physiological response
- Not influenced by hemodynamic and respiratory instability
- Wireless, wearable



Strong and broad IP

- Technology and methods
- 9 approved patents
- 2 patents in process



More than 70 supportive validation studies and 3 theses

- All by independent reserachers
- · More studies planned



CE certified technology, in the process of obtaining FDA approval



Strong team

 lead by professor and medical doctor Hanne Storm



Currently looking for distributors to further develop and expand the market with the new PainSensor

Our team





Professor Hanne Storm
Founder - CEO - Board member

MD.PhD. University of Oslo



Jens Gran

co-Founder - CFO - Chairman of the

board

MSc. Civil engineer, Norwegian
University of Science and Technology
NTNU, MSc Finance, LSE, UK



Rebecca Kaarem CTO - Engineer

MSc. Eindhoven University of Technology, The Netherlands.



Henrik Auråen
CEO*In process

MD. PhD. University of Oslo.

Specializing for surgery, Oslo

University hospital



Mikkel Lager Project and customer follow up

Biomedical Electronic Engineering,
Oslo .



Mark Heuring Sales manager Germany

MSc. Finance. Boston General management program



Professor Johan Ræder Scientific Advisory board,

MD.PhD. University of Oslo



Kartik Karuna Part time technical advisor

M. Sc Electronic System
Engineer



Håkan Dahlqvist Part time regulatory advisor

M Sc. Bio.engineer and previous quality assurance advisor (Intertek)



Thomas Velle
Advisor - Strategy and Business Development

MPH. International business



Professor Larisa Pushkarova

nt Clinical manager

MD.PhD. University of Minsk. Pediatrician


.PhD. University of Minsk. Pediatrician and Anesthesiologist

Why is it important to improve personalized pain management?



Pain is a worldwide problem





Worldwide
+1.5 billion
Individuals lives affected

Focus in **50%**Of doctors visits


Present in **50%** of ICU patients₁

Severe pain experienced by

63%
of surgical patients₂

Pain is a worldwide problem - for the patient





Suffering and reduced quality of life

- Uncomfortable sensations
- Agitation and anxiety
- Undetected pain for those who are unable to communicate their pain

Issues related to over- and under-use of opioids


- Hemodynamic instability
- Delirium (confusion)
- Gut problems (constipation)
- Nausea
- Drowsiness / reduced consciousness

Risk of additional complications

 Physical injuries resulting drowsiness from over-use of opioids

Pain is a worldwide problem - For the economy








Low return on investment (ROI) (staff time)

- Increased length of hospital stay —> hospital expenses increases
- Number of procedures decreases -> revenue decreases
- Hemodynamics are inaccurate



Pain is a worldwide problem - For the caregivers





Pain detection relies on spot checks:

 It is infeasible for health care professionals to constantly observe the patient to detect pain

Pain detection is based on observational pain assessment:

- Time consuming
- Complex
- Based on subjective validation

Pain detection is based on self-reported pain levels

- Many patients are unable to communicate
- Subjective, unspecific

The Solution:

Continuous, real-time pain monitoring with the PainSensor



- Continuous, real-time
- Wireless, wearable
- Low-cost




Connects to a tablet with MedStorm's PSS software



PSM connectivity box to integrate indices with existing patient monitors

*or directly to the new generation Philips monitors





The Pain index is sampled at patient data monitoring systems e.g. Metavision with other vital signs



The PainSensor has different indices and application areas









Pain Index

Awakening Index

Nerveblock Index



Operating theathres

- Pain Index
- Awakening index
- Nerveblock index



Intensive care units

- Pain Index
- Awakening index





Post-operatively

- Pain Index



Neonatal intensive care units (NICUs) and pediatric intensive care units (PICUs)

- Pain Index

The sensor detects skin conductance peaks, correlating with firing in the skin sympathetic nervous system




Based on the fight / flight response: Primitive nociceptive spinal reflex results in Palmar and plantar emotional sweating





- Painful stimulus elicits a skin sympathetic response by the sweat glands, increasing secretion.
- The skin sympathetic responses are detected by measuring changes (peaks) in skin conductance mirroring skin sympathetic nerve activity




Small bursts in the sympathetic nerves give small skin conductance peaks and huge bursts in the sympathetic nerves give huge skin conductance peaks.

Milestones reached, business model, investment needs



Milestones reached





- Transformed PainMonitor into miniutarized, wireless and wearable PainSensor
- 9 approved patents and 2 in process
- Onnectivity to Patient monitors, tablets, and PCs
- More than 70 supportive validation studies and 3 theses
- Connectivity to Philips, Masimo and Mindray monitors
- CE-certified technology and FDA approval in process
- Worldwide sales of the PainMonitor
- Won a tender together with Philips in Switzerland

- Preorders of the PainSensor (60.000 Euro)
 - Established distributor agreements with partners for sales to hospitals in Europe (more in process):
 - Lueag, Switzerland (sales 60.000 Euro 2021 and 400.000 Euros 2022)
 - Eumedics, Austria, in process.
 - IMI, Japan approval in process
 - Hongkong, Philips in process
 - Kina, Philips in process
 - Norway, Vingmed in process
 - Germany, Mark Heruing home care marked and palliative care

Growth potential, business model, and investment needs



Worldwide sales of the PainMonitor

- Mainly for reserach purposes
- The miniutarized PainSensor for clinical use was developed as a result of several requests from customers



Strong growth expected after launch of the PainSensor

Business model

Hardware sales

- PainSenor
- Disposables
- Connectivity (PSM or tablet with software)

Databases and cloud system

Vision of creating our own system.

Service agreements

Ensuring software is always up-to-date, software upgrades, hardware checks.

Reimbursement

 Based on legislation in each area, as pain is mandatory to treat, we are investigating the various reimbursment opportunities.

Plan for future investment to further develop and expand the market with the new PainSensor:

65% Sales and marketing investment

5% Regulatory and IP

10% Business and organization

10% Technology development

10% Overhead


The market



The market is growing



Global Anesthesia Devices Market (\$B, forecast)



- The market for anesthesia devices is expected to grow at 8-10% p.a. to 2027, reaching a market value of ~\$17B globally.
- 21000 depth of anaesthesia monitoring solutions (e.g. BIS) in 2023 (up from 12600 in 2017), at an ASP of USDK 29 (US numbers), in Europe an ASP of 10-15 000 €.

The market


1. Core usecases:

















Operating theatres only

2. Application in operathing theatres:









Pain and nociceptive responses, only

3. Reaction time after stimulus:

1-2 s

4. Works accurate during hemodynamic and

respiratory instabillity:

Yes

68 s

~30 sec

N/A

No

No

No

Future potential and milestones



There are various use-areas for the PainSensor, both in the hospitals cand for home-monitoring (veterinary medicine in progress)



Hospitals



Operating theathres

- Pain Index
- Awakening index
- Nerveblock index



Intensive care units

- Pain Index
- Awakening index



Post-operatively

- Pain Index



Neonatal intensive care units (NICUs) and pediatric intensive care units (PICUs)

- Pain Index

Home-market / Out-patient clinics


















Veterinary medicine

Under development

- already tested and validated on pigs, cats and dogs (horses in process)
- Sales confirmed





New products - road map

2021

2022



Telemedicine – the wireless, miniaturized and wearable PainSensor for home market and hospitals.

Communication and applications in process with Dignio (Norway) and Caretakermedical (US and Europe) – EC grant with Amsterdam Medical Centre – The palliative pain team.



The PainSensor as **consumer product** connected to smart phones, available for **pharmacies and groceries** shops.



In veterinary medicine: **5 million** pets/year in the US are anesthetized.



Monitoring chronic pain: **200 million** procedures/year need chronic pain monitoring in the US.



10 million patients/year need objective chronic pain diagnosis in US.

Thank you for your attention!

